Cogent Biosciences, Inc. (COGT): Price and Financial Metrics
GET POWR RATINGS... FREE!
COGT Stock Price Chart Interactive Chart >
COGT Price/Volume Stats
|Current price||$14.43||52-week high||$18.07|
|Prev. close||$14.75||52-week low||$3.79|
|Day high||$15.06||Avg. volume||721,261|
|50-day MA||$12.01||Dividend yield||N/A|
|200-day MA||$11.27||Market Cap||661.17M|
Cogent Biosciences, Inc. (COGT) Company Bio
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a Âbolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Most Popular Stories View All
COGT Latest News Stream
|Loading, please wait...|
COGT Latest Social Stream
View Full COGT Social Stream
Latest COGT News From Around the Web
Below are the latest news stories about COGENT BIOSCIENCES INC that investors may wish to consider to help them evaluate COGT as an investment opportunity.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from Phase 2 SUMMIT trial in NonAdvSM patients Rapidly progress bezuclastinib in 2nd-line Gastrointestinal Stromal Tumors (GIST), with planned clinical update from lead-in portion of Phase 3 PEAK trial in 1H23, and expansion to >100 global clinical sites this yearSelect clinical candidates from ongoing FGFR
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2023 at 7:30 a.m. PT/10:30 a.m. ET. A live webcast of the presentation will be available on the Investors &
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
- 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up - Rapid and deep responses seen including first confirmed CR at 20 weeks; 77% of patients with at least 2 cycles of treatment had complete clearance of bone marrow mast cell aggregates - Favorable safety and tolerability profile with no related cognitive effects or reported intracranial bleeding events - Cogent to host investor webcast Monday, December 12 at 8:00 a.m. ET WALTHAM, Mass. and BO
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 6
COGT Price Returns